Guangping Gao, PhD

• Lacticaseibacillus paracasei subsp. paracasei Q- 1 Exhibits Good Safety and Effectively Prevents Escherichia coli K99-Induced Diarrhea in Mice

• Drug resistance and pathogenicity characteristics of Escherichia coli causing pneumonia in farmed foxes

• A deep learning model trained on expressed transcripts across different tissue types reveals cell-type codon-optimization preferences

• The curious case of AAV immunology

• A single amino acid variant in the variable region I of AAV capsid confers liver detargeting

• Cell-penetrating peptide-grafted AAV2 capsids for improved retinal delivery via intravitreal injection

• Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy

• BCKDHA-BCKDHB digenic gene therapy restores metabolic homeostasis in two mouse models and a calf with classic maple syrup urine disease

• Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations

• Rhodoquinone carries electrons in the mammalian electron transport chain

• A comprehensive atlas of AAV tropism in the mouse

• AAVone: A Cost-Effective, Single-Plasmid Solution for Efficient AAV Production with Reduced DNA Impurities

• The 2024 Nobel Prize: Impact of the Discovery of miRNA on the Field of Gene Therapy

• In vivo evolution of env in SHIV-AD8EO-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig

• Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review

• A Comprehensive Atlas of AAV Tropism in the Mouse

• Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency

• The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2

• Improving the Assessment of Risk Factors Relevant to Potential Carcinogenicity of Gene Therapies: A Consensus Article

• Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders

• Engineering a targeted and safe bone anabolic gene therapy to treat osteoporosis in alveolar bone loss

• Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy

• AAV5 Delivery of CRISPR/Cas9 Mediates Genome Editing in the Lungs of Young Rhesus Monkeys

• Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy

• Oligonucleotide therapies for nonalcoholic steatohepatitis

• Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus

• Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency

• Adeno-associated virus as a delivery vector for gene therapy of human diseases

• Producing high-quantity and high-quality recombinant adeno-associated virus by low-cis triple transfection

• Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases

• Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor

• Domain-inlaid Nme2Cas9 adenine base editors with improved activity and targeting scope

• AAV-based gene editing of type 1 collagen mutation to treat osteogenesis imperfecta

• Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis

• Aurora kinase B disruption suppresses pathological retinal angiogenesis by affecting cell cycle progression

• A Fluorescent Reporter Mouse for In Vivo Assessment of Genome Editing with Diverse Cas Nucleases and Prime Editors

• Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo

• NIIMBL's viral vector program: A cross-gene therapy community collaboration to transform viral vector development and manufacturing

• Non-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice

• AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans Progressiva

• Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation

• Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling

• Querying Recombination Junctions of Replication-Competent Adeno-Associated Viruses in Gene Therapy Vector Preparations with Single Molecule, Real-Time Sequencing

• C9orf72 poly(PR) aggregation in nucleus induces ALS/FTD-related neurodegeneration in cynomolgus monkeys

• Durable contraception in the female domestic cat using viral-vectored delivery of a feline anti-Müllerian hormone transgene

• A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors

• Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism

• Schnurri-3 inhibition suppresses bone and joint damage in models of rheumatoid arthritis

• Engineering Nme2Cas9 Adenine Base Editors with Improved Activity and Targeting Scope

• Rescue of GM3 synthase deficiency by spatially controlled, rAAV-mediated ST3GAL5 delivery